leukaemic disease, this led to further research in different neoplasms such as lung cancer where it was seen that the high expression of VISTA/PD-1H is directly related to low tumour mutational load, observing the immunomodulatory role of VISTA/PD-1H these findings suggest that a combination of drugs against PD-1 and VISTA could induce more rapid and profound responses with immune checkpoint inhibitors (ICIs). This evidence concerns the gene VSIR and lung cancer.